Tri Locum Partners LP Madrigal Pharmaceuticals, Inc. Transaction History
Tri Locum Partners LP
- $374 Million
- Q3 2024
A detailed history of Tri Locum Partners LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Tri Locum Partners LP holds 43,287 shares of MDGL stock, worth $13.2 Million. This represents 2.45% of its overall portfolio holdings.
Number of Shares
43,287
Previous 65,352
33.76%
Holding current value
$13.2 Million
Previous $18.3 Million
49.83%
% of portfolio
2.45%
Previous 4.73%
Shares
8 transactions
Others Institutions Holding MDGL
# of Institutions
298Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$759 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$625 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$621 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$610 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$604 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.24B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...